EP3870249A1 - Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né - Google Patents

Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né

Info

Publication number
EP3870249A1
EP3870249A1 EP19804634.4A EP19804634A EP3870249A1 EP 3870249 A1 EP3870249 A1 EP 3870249A1 EP 19804634 A EP19804634 A EP 19804634A EP 3870249 A1 EP3870249 A1 EP 3870249A1
Authority
EP
European Patent Office
Prior art keywords
fluid
oxygen
flow system
amniotic fluid
flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19804634.4A
Other languages
German (de)
English (en)
Inventor
Michael Tchirikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3870249A1 publication Critical patent/EP3870249A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1698—Blood oxygenators with or without heat-exchangers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G11/00—Baby-incubators; Couveuses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/32—Oxygenators without membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/049—Toxic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/14—Female reproductive, genital organs
    • A61M2210/1433—Uterus
    • A61M2210/1466—Umbilical cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2240/00—Specially adapted for neonatal use

Definitions

  • the present invention relates to a device and a method for the life support of a person, preferably a newborn, in particular an extremely premature baby, between the 21/0 and 28/0 week of pregnancy (SSW).
  • SSW 21/0 and 28/0 week of pregnancy
  • the surviving premature babies suffer from retinopathy with a severity of greater than 3 (relative blindness) in 89% of cases. In the 23rd week of pregnancy, 42% are affected. Only a percentage of less than 20% of premature babies survive until discharge from the hospital without developing necrotizing enterocolitis, sepsis, meningitis, bronchiopulmonary hypoplasia and / or pronounced cerebral hemorrhage in premature babies under the 24th week of pregnancy (Stoll et al. JAMA 2015).
  • bronchopulmonary dysplasia The development of bronchopulmonary dysplasia is 72% in extremely premature babies ⁇ 25/0 week of pregnancy (Noelle Younge et al., Survival and Neurodevelopmental Outcomes among Periviable Infants, The New England Journal of Medicine, February 16, 2017 vol. 376 no. 7). Pneumothorax often occurs when ventilating extremely immature lungs. The immature inadequate lungs are in most cases unable to provide normal, permanent oxygen supply to the placenta, which leads to hypoxic brain damage and / or pronounced brain hemorrhage.
  • placenta takes over the oxygen supply.
  • Other important placental functions are, for example, a transplacental active and / or passive
  • Some substances such as amino acids, hormones, NO are also synthesized in the placenta itself.
  • the fetal metabolites such as bilirubin or C0 2 are disposed of via the placenta. The maternal kidneys and lungs then take on the disposal function.
  • the arterial blood is transported to the uterus through the uterine vessels.
  • the spiral arteries bring the blood over the basal plate of the placenta into the placental intervillous space.
  • the fetal placental blood is located in the fetal capillaries of the placental villi and is separated from the maternal blood by a thin layer of tissue syncytium and cytotrophoblast.
  • the 0 2 - binding curve of fetal hemoglobin is steeper in laboratory conditions than that of maternal blood. Due to the low physiological fetal pH value, the Hb affinity is very similar to the adult Hb affinity under normal conditions.
  • Oxygen binding curve is shifted to the right by the lowering of the pH.
  • Hemoglobin releases the oxygen in the fetal tissue more easily due to the lowering of the pH.
  • the C0 2 - and H + influence on the 0 2 affinity of hemoglobin is also referred to as the Bohr effect. Dissociation of carbonic acid is promoted the less the fetal
  • Hemoglobin is loaded with 0 2 (Haldane effect).
  • Hemoglobin concentration increases from 10-12 g / dl in the 17th / 18th SSW on 14-15 g / dl at
  • WO 2018/171905 A1 describes an artificial uterine system for the life support of newborns, especially of extremely premature babies between the 21/0 and 28/0
  • the US 2014/0255253 A1 describes an artificial uterus, which with a
  • Oxygen supply device for the premature baby is equipped.
  • the device comprises a gas permeable membrane and a vascular network over which, for example
  • Oxygen is supplied via an oxygenator via the umbilical cord using a umbilical catheter
  • WO 2014/145494 A1 Another possibility of oxygenating a premature baby is described in WO 2014/145494 A1, in which the circulatory system of the premature baby is coupled to an extracorporeal membrane, which is part of an oxygen supply system.
  • the oxygenator enriches the fetal blood with oxygen.
  • WO 2016/154319 A1 describes an artificial placenta in which microfluidic channels are provided which are arranged between a membrane in such a way that liquid can be transported through the membrane in order to supply the fetus with nutrients, for example.
  • the regulation of the gas exchange by the pressure, amniotic fluid velocity along the membranes is not described.
  • cell layers are of at least two
  • the first cell type is, for example, primary human placental villous
  • Endothelial cells while the second cell type includes choriocarcinoma cells.
  • Mass transfer through a membrane is disclosed, which is particularly suitable for use as Blood oxygenator is suitable.
  • Extracorporeal membrane oxygenation is often performed to replace lung function.
  • ECL extracorporal life support
  • Hemodynamic relief of the heart is possible because it supports the circulatory system.
  • the blood is transported from the patient's venous system by means of a pump and, after passage through the oxygenator, is returned to the arterial system.
  • Oxygen supply to the organism is made up of the ECMO / ECLS flow and the patient's remaining circulatory function.
  • extracorporeal circulation is usually done through cannulas.
  • the systems require blood heparinization to avoid thrombosis in the artificial system.
  • the other problem is the destruction of erythrocytes with consequences of fetal anemia and an increase in the bilirubin concentration.
  • Oxidative stress as an imbalance between free radicals and antioxidant defense mechanisms, is one of the main factors in the poor outcome of pregnancy (Sultana et al. 2017 Am J Reprod Immunol. 2017 May; 77 (5)). Side effects may include hemolysis and embolism when using such oxygenators. You can also use a
  • the alveolar space of the human lungs is coated with surfactant.
  • the surfactant mainly consists of phospholipids and is synthesized by type II pneumocytes and secreted into the alveoli in order to avoid surface tension.
  • the alveolar epithelial cells and the endothelial cells lie between the capillary blood and the air. There is no direct contact between the blood and the air.
  • the activated (blood) clotting time (ACT) of the fetuses is increased to 150-180 s when using an oxygenator with heparin (10-400 UPS / h) in order to avoid thrombosis of the ECMO / ECL system .
  • the crux of the invention device is an artificial flow system, which consists of a number there are fluid-permeable elements, for example stacked or lamellar membranes or micropore material (eg tubes), which enables an efficient 0 2 - / C0 2 exchange in fetal blood, similar to a gill system in fish. It is envisaged that the oxygen dissolved in oxygenated amniotic fluid or present in an artificial uterine space via the invention
  • fetal blood is branched from the blood vessels of the umbilical cord.
  • the fetal blood is branched from the blood vessels of the umbilical cord.
  • the system an oxygenation of the amniotic fluid and not the fetal blood.
  • the oxygenated amniotic fluid flows through the
  • a plasma replacement solution can also be used.
  • the flow system is preferably arranged in a container (i.e. housing or lumen) in which the fetus is also located.
  • This container serves as an artificial one
  • the flow system is located outside the artificial uterus in a separate housing.
  • a container or housing can be dispensed with completely, i.e. the flow system itself is not integrated in any container.
  • the membranes or the micropore material of the flow systems can be connected to one another either in series or in parallel in the direction of flow.
  • the flow system is constructed like a gill system, i.e. it includes one with the oxygenated amniotic fluid
  • the gill-like flow system enables efficient gas, electrolyte exchange and toxin and waste product disposal, e.g. of bilirubin, ammonia, nitrogen. Osmoregulation via ion transport is also possible.
  • the present invention is based on the idea that the fetus develops in the amniotic fluid.
  • a gas exchange takes place between the fetal blood and the modified amniotic fluid enriched with oxygen or an oxygen-containing gas mixture via the ultra-thin fetal skin, the mucous membranes and the fetal intestine of the fetus.
  • the gas mixture preferably comprises oxygen (0 2 ), carbon dioxide (C0 2 ) and / or nitrogen (N 2 ) .
  • Some living beings use a gill system for breathing, ie fish, crustaceans and molluscs, which Supply the organism with oxygen. The gills take over next to the
  • the flow system according to the invention comprises a number of fluid-permeable elements which work according to the gill principle.
  • the fluid-permeable elements can have a lamella-like, comb-like, leaf-like, tuft-like or tree-like structure, so that the largest possible surface for gas exchange (0 2 / C0 2 ) can arise.
  • the 0 2 exchange to the fetal blood preferably takes place via the countercurrent principle, which is greatly improved compared to conventional problem solutions.
  • the modified amniotic fluid enriched with oxygen or the oxygen-containing gas mixture is passed through the fluid-permeable elements of the flow system, while the fetal blood is glided past the outside of the fluid-permeable elements.
  • the gill structure according to the invention is approximately 24 times higher than that of oxygen, the passive diffusion in the tissue being mainly dependent on the diameter of the respective gas molecule.
  • oxygen defines 0 2 with a molecular weight of 32 faster than C0 2 with a molecular weight of 44.
  • marine animals such as fish are able to extract up to 90% of the available oxygen from the water with their gill system.
  • the device according to the invention initially comprises a closed container which serves to hold the fetus and the flow system.
  • the fetus is in modified amniotic fluid and is supplied with oxygen or the oxygen-containing gas mixture and other vital substances via its umbilical cord.
  • oxygen or the oxygen-containing gas mixture and other vital substances via its umbilical cord.
  • Each flow system consists of a larger number of fluid-permeable elements, for example of> 5, preferably> 10 fluid-permeable elements, preferably> 50 fluid-permeable elements.
  • fluid-permeable elements for example of> 5, preferably> 10 fluid-permeable elements, preferably> 50 fluid-permeable elements.
  • These can consist, for example, of membranes, tubes or micropore material.
  • the flow system further comprises one or more flow lumens which are used for
  • Modified (or artificial) amniotic fluid is amniotic fluid that has been adapted to the fetus and in which one or more components have been added or omitted.
  • the components are, for example, electrolytes such as NaCl or KCl, or drugs, nutrients or medical devices.
  • amniotic fluid is guided from the outside in the longitudinal direction through the fluid-permeable elements of the flow system.
  • Oxygenated amniotic fluid oxygenated amniotic fluid
  • the fetal blood could be passed through the fluid-permeable elements.
  • the amniotic fluid flows around the fluid-permeable elements from the outside, i.e. the membranes or capillaries.
  • the umbilical cord blood vessels are fixed using a fixation system, for example a stent.
  • At least one connection is provided on the container for introducing amniotic fluid and / or respiratory gas (oxygen, oxygen gas mixture or carbogen) in order to conduct modified amniotic fluid and / or respiratory gas into or to the flow system.
  • the gill-like design of the at least one flow system also enables the function of a dialysis system to dispose of substances.
  • the modified amniotic fluid for the gill system is provided and used separately from the amniotic fluid of the artificial uterine system in order to adjust the blood parameters of the fetus and / or the fetal treatment via the
  • the modified amniotic fluid provided in a separate container is preferably optionally mixed with drugs, heparin, vitamins, proteins, growth factors and / or hormones. It is particularly preferred that the
  • Micro-element administration and / or a toxin and waste product disposal for example of bilirubin, ammonia, nitrogen, and / or plasma osmoregulation via the separate Amniotic fluid system takes place.
  • a supply via the artificial uterine system is also possible.
  • the artificial gill system is located outside the artificial uterine system in order to reduce the noise pollution of the fetus. This can be within another container or housing. In a preferred one
  • Embodiment provides that the flow system manages entirely without a container, i.e. it is located outside the artificial uterus and is not itself enclosed by a housing.
  • the device according to the invention is constructed like an artificial uterine system, so that the fetus develops in the modified amniotic fluid in the interior of the container.
  • the fetal oxygen requirement in fetuses is about 5 ml / min / kg (Campbell et al., J. Physiol 1966; 182: 439-464).
  • the oxygen requirement is around 2 to 4 ml / min.
  • One ml of oxygen weighs around 1.34 mg.
  • an oxygen content in amniotic fluid of 7 to 50 mg / l, the fetal
  • the fluid-permeable elements preferably comprise membranes, membranes with
  • Micropores polymethylpentene
  • PNP material polymethylpentene
  • membranes with micropores membranes with micropores.
  • other fluid-permeable elements are also covered by the invention.
  • the flow system is connected to the child's vascular system via the connecting elements (ie via the child's umbilical cord), preferably via a port system.
  • the fumigated amniotic fluid eg provided as 0 2 or 0 2 / C0 2 or 0 2 / C0 2 and nitrogen mixture
  • the fumigated amniotic fluid is arranged in a first embodiment directly above the stack
  • a pressurized container with amniotic fluid is preferably present.
  • a pump can also be used, which is the amniotic fluid enriched with oxygen or the oxygen-containing gas mixture passed through the fluid permeable elements.
  • the oxygen supply can also take place directly by gassing the interior of the container with oxygen or an oxygen-containing gas mixture. Appropriate connections for the supply of breathing gas are available for this. This allows the individual proportions for the oxygenation of the fetus to be set precisely, in particular the ratio of amniotic fluid / gas,
  • Amniotic fluid / oxygen can range from 0.1 / 10 to 9.9 / 10.
  • Gas exchange is determined by the speed of the flow through the system
  • amniotic fluid flowing through the fluid volume, the direction / opposite direction, the frequency (oscillation 0-1000 Hz), the 0 2 supply and / or gas mixture supply and / or regulated by a pressure change in the flow system.
  • This preferably includes
  • Flow system is integrated. This is preferably a pressure flap that can be mechanically adjusted in advance.
  • the flap can be opened and closed mechanically and / or digitally.
  • the countercurrent principle facilitates the 0 2 uptake from the amniotic fluid into the fetal blood, similar to a natural gill system.
  • the fetal blood flows directly through the fluid-permeable elements, preferably via tubes or a membrane system, where gas exchange takes place.
  • the modified amniotic fluid (with or without oxygen) or an amniotic fluid / gas mixture (ratio amniotic fluid / gas from 0.1 / 10 to 9.9 / 10) is by the modified amniotic fluid (with or without oxygen) or an amniotic fluid / gas mixture (ratio amniotic fluid / gas from 0.1 / 10 to 9.9 / 10) is by the modified amniotic fluid (with or without oxygen) or an amniotic fluid / gas mixture (ratio amniotic fluid / gas from 0.1 / 10 to 9.9 / 10) is by the modified amniotic fluid (with or without oxygen) or an amniotic fluid / gas mixture (ratio amniotic fluid / gas from 0.1 / 10 to 9.9 / 10) is by the modified amniotic fluid (with or without oxygen) or an amniotic fluid
  • the water pressure in the system on the fluid-permeable elements can be increased via the pressure valve.
  • the pressure can be increased periodically or kept at a constant level.
  • the pressure in the flow system can also be controlled by gassing the amniotic fluid.
  • the modified amniotic fluid in the flow system is preferably oscillated via the pressure valve or via a feed device, preferably at a frequency of 0-1000 Hz.
  • the flow system i.e. the gill system
  • the flow system is used independently of the artificial uterine system, for example to replace or supplement the lung function in children or adults.
  • the modified amniotic fluid can also be replaced by other solutions or liquids, for example blood, plasma, nutritional solutions, salt solutions (NaCI), plasma substitute solutions, sea water, etc.).
  • the flow system according to the invention preferably works on the principle of acceleration, in which the amniotic fluid (or a other liquid) is accelerated with a pump, which makes the oxygen / C0 2 exchange more efficient.
  • the Device additionally an additional absorber to dispose of substances such as cytokines, toxins, ammonia, bilirubin, myoglobin, creatinine, inflammatory substances or degradation products from the fetal blood.
  • the cytokines are, for example, IL-6, IL-8, IL-10, TNA-alfa, IFN.
  • the modified amniotic fluid is preferably preheated to a temperature between 37 ° and 39 ° C. by means of a heating device.
  • the interior of the container (corresponding to an artificial uterus) is also kept at a temperature between 37 ° and 39 ° C.
  • a thermoregulator can be used to temporarily cool down to a temperature of up to around 34 ° C to reduce organ damage after asphyxia.
  • the flow system preferably further comprises a measuring device for
  • composition of the modified amniotic fluid is also crucial for successful life support and further development of the premature baby.
  • amniotic fluid used according to the invention therefore includes a preferred one
  • Embodiment a nutrient composition, the concentrations of which with the
  • the space preferably comprises the artificial one
  • Uterus of the uterine system according to the invention modified amniotic fluid, which has the composition of US 9,072,755B2.
  • trace elements such as Boron, chromium, iron, fluorine, iodine, cobalt, lithium, manganese, molybdenum, nickel, silicon, vanadium, amino acids, growth factors, vitamins and
  • Hormones can supplement the modified amniotic fluid.
  • the amniotic fluid is preferably preheated to a temperature between 37 and 39 ° C. before being introduced into the artificial uterus, and gassed with oxygen or an oxygen-containing gas mixture at the same time.
  • the fetal 0 2 saturation becomes 60-90% in the artificial after the umbilical cord Uterine system held in the fumigated amniotic fluid by the flow system.
  • the present invention further relates to an ex vivo method for the maintenance of life of a person, preferably a newborn, in particular an extremely premature baby between the 21/0 and 28/0 week of gestation, in order to maintain his life functions.
  • the features previously described for the device also apply analogously to the method.
  • the procedure is applicable to children and adults.
  • amniotic fluid or a plasma replacement solution enriched with oxygen or oxygen-containing gas mixture is supplied to a container in which there is at least one flow system, which consists of a number of fluid-permeable elements and connecting elements for connection to the catheters for the umbilical arteries and umbilical vein People (e.g.
  • a flow lumen for the passage of modified amniotic fluid or the plasma replacement solution through the fluid-permeable elements, as well as at least one connection for introducing modified oxygenated amniotic fluid, plasma replacement solution and / or respiratory gas into the flow system.
  • modified amniotic fluid or plasma replacement solution or the blood Either the amniotic fluid or plasma replacement solution or the blood through the
  • a pressure between 5 mbar and 5 bar is preferably maintained in the flow system.
  • the premature baby is preferably a fetus born before the 28th week of pregnancy.
  • the uterine system according to the invention and the ex vivo method also work in children who have a limited life expectancy due to lung insufficiency, for example due to congenital defects or due to functions that have not yet been developed, as can be ascertained, for example, in neonates with hypoplasia of the lungs.
  • permanent treatment of lung insufficiency and also damage to respiratory tract or lungs which are caused, for example, by burns, are possible.
  • the complete analysis of the data can be done via a control center for each individual uterine system.
  • the parents can, as needed or desired, e.g. via a smartphone, can be integrated into fetal video monitoring or vital signs monitoring.
  • This type of parent integration also enables audio and / or video based communication, which enables interaction between the parent and the child. This is particularly important because the mother often suffers from fear of loss or failure.
  • An audio and / or video based interaction between mother and fetus, e.g. via a smart phone, is among other things advantageous to avoid depression of the mother.
  • a variant provides that, for example, increased heartbeats of the child, after filtering out the device noises, are transmitted to the mother in real time via a communication device (e.g. smartphone).
  • a communication device e.g. smartphone
  • noises from the mother and / or the father e.g. heartbeat, voice, breathing noises, possibly bowel noises
  • live real time
  • devices which enable high-frequency data acquisition and analysis.
  • the analysis includes in particular the use of density prediction methods, a corresponding risk forecast and the implementation of regime switching models.
  • the device according to the invention comprises a
  • Fetus in the artificial uterine system and the mother or father is possible.
  • the device is preferably equipped with an audio system with which one
  • acoustic heart actions of the fetus are recorded and, if necessary, digitally amplified in order to transmit this information via a network, for example to a smartphone of the mother and / or the father.
  • the device according to the invention comprises more than one flow system, preferably two or more flow systems, which are either connected in parallel or in series. This makes it possible to run several systems in parallel or independently of one another. This is important, for example, when changing the oxygenator. If necessary, the existing redundancy can also be used to replace a defective system with a functioning system in order to ensure, for example, the 0 2 gassing, an increase in pressure in the flow system or an increase in the amniotic fluid flow and thus to maintain the physiological functions of the child. These functions should also be networked so that the systems can be monitored and, if necessary, controlled worldwide via a network.
  • the recording, recording and transmission of the vital data of the fetus and other information, such as audio information, are preferably transmitted via an encrypted network.
  • the vital functions should be regulated via control software and a control integrated in the uterine system (e.g. for gas exchange, amniotic fluid supply, the supply of fetal blood). The control takes over here
  • the invention has significant advantages over conventional oxygenators.
  • the inventor of the present invention has found that those described in the prior art
  • Replacing the gas mixture with perfusion with a 0 2 enriched modified amniotic fluid reduces the risk of thrombosis and heparin, contributes to the physiological stabilization of the fetal blood gases and increases the duration of the workability of the
  • Fig. 1 shows a first embodiment of the device in which modified oxygenated
  • Amniotic fluid flows through membranes of the flow system (gill system),
  • Fig. 2 shows another embodiment in which the fetal blood through the flow system
  • 3 shows a variant of an artificial uterine system
  • 4 shows a further variant with two flow systems
  • Fig. 5 shows a variant with a second amniotic fluid system for supplying the fetus
  • Fig. 6 shows the structure of an embodiment of the artificial gill system.
  • the device comprises a container 10 in which a flow system 21 is arranged.
  • Modified amniotic fluid (preferably preheated) is introduced into the flow system 21 via a line 14 via a connecting piece 18 via a pump system via a connection 12.
  • the amniotic fluid can be oxygenated via an oxygen line 16.
  • the artificial space inside the container can be gassed with medical breathing air via its own gas connection.
  • the flow system 21 itself consists of a number of more than 20 fluid-permeable elements, which are 0 2 - and C0 2 - permeable. These are preferably lamellar ones
  • the internal pressure of the gill system can be regulated at a frequency of 0-1000 Hz, preferably 10-80 Hz, via a pressure valve 24.
  • Fetal blood is conducted according to the countercurrent principle via appropriate flow lumens 20 around the membrane of the flow system 21.
  • Oxygen and fetal blood By increasing the flow rate, the efficiency of the 0 2 / C0 2 exchange can be increased considerably.
  • the pressure in the flow system is preferably maintained between 5 mbar and 5 bar. Accesses for oxygen or a gas mixture are provided. Furthermore, a gas mixture of 0 2 , C0 2 and N 2 can also be applied. Alternatively or additionally, the carbogen gas mixture or from 0 2 can also be applied directly to the amniotic fluid.
  • the pressure valve 24 Via the pressure valve 24, the amount of amniotic fluid, the speed and the pressure in the flow system 21 are regulated in addition to the amniotic fluid pump (not shown).
  • the pressure valve 24 can be controlled mechanically or digitally.
  • Via a measuring lead can be taken for a measuring device (not shown), for example to determine the oxygen saturation in the blood before and after oxygenation.
  • FIG. 2 shows a further variant in which the fluid-permeable elements 22 of the
  • Flow system 21 are flowed through directly by the fetal blood.
  • the modified amniotic fluid flows around the fluid-permeable elements 22, i.e. the capillaries or membranes.
  • the container 10 comprises a flow-through system 21.
  • a connection 12 is used to supply modified amniotic fluid, which is preferably provided in a preheated reservoir 42.
  • the storage container 42 is preferably equipped with a thermostat and a pump.
  • a preheating temperature of 37 ° to 39 ° C. in the reservoir 42 for the modified amniotic fluid of the gill system is preferred
  • the amniotic fluid can be oxygenated directly from an oxygen container 40.
  • direct gassing of the artificial space of the container 10 and / or of the flow system 21 with oxygen can take place.
  • Appropriate sensors 48 make it possible to monitor vital functions and to forward them via a network.
  • the recording and playing of noises and sounds are possible via an audio device 43.
  • Data are transmitted to corresponding servers 44 via a network 41 and ultimately analyzed using an analysis device 46.
  • the entire system can also be regulated in the same way.
  • a system is shown analogously, which is constructed similarly to the variant of Fig. 3.
  • the gassing is carried out with a gas mixture of 0 2 , C0 2 , N 2 provided in container 40.1, 40.2, 40.3.
  • the addition of CO 2 can be useful, for example, for the relaxation of vessels.
  • two flow systems 21 are provided.
  • the data can also be exchanged via a smartphone 50, ie important vital functions, audio files or other information from and to the artificial
  • Uterine systems can be replaced directly by the mother / father or another person who monitors the uterine system.
  • FIG. 5 shows a further developed system in which an additional container 60 with modified amniotic fluid is provided in addition to the storage container 42 filled with modified modified amniotic fluid.
  • the fetus is supplied with the substances via the flow system 21, i.e. about artificial enriched with the substances
  • Amniotic fluid which is provided by the reservoir 42.
  • This is a supply fetus with medication, including heparin, vitamins, proteins, growth factors and / or hormones.
  • the neonatal care can be ensured or prophylactic or therapeutic treatment can be carried out.
  • blood parameters of the fetus can be set individually.
  • Water-soluble substances which dissolve in the modified amniotic fluid are preferably used.
  • the system has the advantage of preventing the premature baby from being overwashed, since it prevents an increase in volume due to the absorption of too much fluid. Furthermore, decompensation occurring in other systems or treatment methods is prevented, because at least some of the active ingredients and nutrients can be absorbed via the gill system in order to avoid unnecessary volume loading of the fetus.
  • the modified amniotic fluid Water-soluble substances which dissolve in the modified amniotic fluid.
  • Amniotic fluid of the gill system reservoir 42 is separate from the amniotic fluid of the uterine system in the container 60.
  • the administration of heparin or other antithrombotic medication can be locally via the artificial gill system
  • external housing 52 is arranged as an external gill system. Via a port system
  • Amniotic fluid in the reservoir 42 can be cooled down to up to 4 ° C
  • valve 53 is regulated via a valve 53.
  • the variant is the function of the one equipped with a thermostat and a pump
  • Storage container 42 integrated in a housing 52.
  • the housing 52 can accordingly

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)

Abstract

La présente invention concerne un dispositif et un procédé pour le maintien en vie d'un humain, de préférence d'un nouveau-né, en particulier d'un très grand prématuré entre la 21ème et la 28ème semaine de grossesse (SSW). Le dispositif comprend au moins un système d'écoulement (21), comprenant un certain nombre d'éléments (22) perméables aux fluides et d'éléments de liaison (26, 28) pour le raccordement à des cathéters d'artère (30) ombilicale et à des cathéters de veine (32) ombilicale du nouveau-né et une lumière (20) d'écoulement pour le passage de liquide amniotique modifié enrichi en oxygène ou en mélange gazeux contenant de l'oxygène à travers les éléments (22) perméables aux fluides, ainsi qu'au moins un raccord (12) pour l'introduction du liquide amniotique modifié enrichi en oxygène ou en mélange gazeux contenant de l'oxygène dans le système d'écoulement (21), le système d'écoulement (21) étant configuré de sorte que le liquide amniotique modifié enrichi en oxygène ou en mélange gazeux contenant de l'oxygène est guidé à travers les éléments (22) perméables au fluide du système d'écoulement (21), tandis que le sang fœtal est guidé devant la face extérieure des éléments (22) perméables aux fluides par l'intermédiaire de la lumière (20) d'écoulement, ce qui a pour effet qu'un échange gazeux s'effectue.
EP19804634.4A 2018-10-25 2019-10-25 Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né Withdrawn EP3870249A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018126634.0A DE102018126634A1 (de) 2018-10-25 2018-10-25 Vorrichtung mit künstlichem Kiemensystem und Verfahren für die Lebenserhaltung eines Neugeborenen
PCT/EP2019/079213 WO2020084125A1 (fr) 2018-10-25 2019-10-25 Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né

Publications (1)

Publication Number Publication Date
EP3870249A1 true EP3870249A1 (fr) 2021-09-01

Family

ID=68581746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19804634.4A Withdrawn EP3870249A1 (fr) 2018-10-25 2019-10-25 Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né

Country Status (6)

Country Link
US (1) US20210308350A1 (fr)
EP (1) EP3870249A1 (fr)
JP (1) JP2022509400A (fr)
CN (1) CN113226399A (fr)
DE (1) DE102018126634A1 (fr)
WO (1) WO2020084125A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4062919A1 (fr) 2021-03-24 2022-09-28 Prenatal International GmbH Au moins une composition à base de liquide amniotique humain destinée à l'utilisation dans un procédé de nutrition entérale, de supplémentation nutritionnelle entérale et/ou de traitement et/ou d'alimentation des couches peu capillaires
CN115919584B (zh) * 2023-01-09 2023-05-26 首都儿科研究所附属儿童医院 一种仿生子宫系统
CN115708748B (zh) * 2023-01-09 2023-04-28 首都儿科研究所附属儿童医院 一种可置入多个手术器械的仿生子宫系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556489A (en) * 1983-03-09 1985-12-03 Shiley Incorporated Membrane oxygenator
US20070010005A1 (en) * 2005-07-08 2007-01-11 James Sitzmann Neonatal support system and related devices and methods of use
US20090018484A1 (en) * 2007-07-11 2009-01-15 Levitov Alexander B System device and method for oxygenation
RU2376969C1 (ru) * 2008-06-11 2009-12-27 Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Устройство для выхаживания недоношенных новорожденных
TR201911076T4 (tr) 2011-01-05 2019-08-21 Prenatal Int Gmbh Klorür içeriği azaltılmış fosfolipit içeren veya içermeyen hipotonik sulu bileşim.
EP2747807B1 (fr) 2011-08-23 2017-12-20 McMaster University Placenta artificiel
CA2905619C (fr) 2013-03-15 2021-06-01 The Children's Hospital Of Philadelphia Systeme de support de vie extracorporel et ses procedes d'utilisation
US10633623B2 (en) 2015-03-24 2020-04-28 The Trustees Of The University Of Pennsylvania Artificial placenta and methods of preparation
RU2020114672A (ru) * 2015-06-19 2020-05-22 Дзе Чилдрен'З Хоспитал Оф Филадельфия Способ и устройство для экстракорпорального жизнеобеспечения недоношенного плода
US10709827B2 (en) * 2015-10-14 2020-07-14 Technische Universität Wien Membrane catheter
WO2018171905A1 (fr) * 2017-03-21 2018-09-27 Universitätsklinikum Halle (Saale) Système d'utérus synthétique et placenta
US10441490B2 (en) * 2018-01-09 2019-10-15 Amnion Life, LLC Systems, methods, and devices for artificial placentas and amniotic bed incubators

Also Published As

Publication number Publication date
DE102018126634A1 (de) 2020-04-30
JP2022509400A (ja) 2022-01-20
US20210308350A1 (en) 2021-10-07
CN113226399A (zh) 2021-08-06
WO2020084125A1 (fr) 2020-04-30

Similar Documents

Publication Publication Date Title
EP3600206B1 (fr) Système d'utérus synthétique et placenta
JP6983793B2 (ja) 体外での肺補助のための方法
EP3870249A1 (fr) Dispositif à système de branchies artificielles et son utilisation pour le maintien en vie d'un nouveau-né
EP2488231B1 (fr) Dispositif de traitement d'un patient souffrant d'une insuffisance cardiaque, d'un arrêt cardiaque, d'un arrêt circulatoire ou d'un accident vasculaire cérébral
US11833282B2 (en) Method for extracorporeal carbon dioxide removal
US9492603B2 (en) Artificial placenta
JPH048408B2 (fr)
US11344656B2 (en) Methods and systems for removing carbon dioxide
Bird Artificial placenta: Analysis of recent progress
EP3041495A1 (fr) Préparations pour une meilleure oxygénation des tissus par respiration péritonéale
Carr et al. Peritoneal perfusion with oxygenated perfluorocarbon augments systemic oxygenation
Jacobs et al. Extracorporeal carbon dioxide removal during continuous renal replacement therapy as adjunctive therapy
EP2020247A2 (fr) Conditionnement de sang d'un patient à l'aide de gaz
DE202019005458U1 (de) System zur extrakorporalen Hyperthermie-Perfusions-(EHP-)Therapie
RU2783826C2 (ru) Способы и системы для удаления двуокиси углерода
Wallace et al. Acidaemia enhances the inhibitory effect of hypoxia on fetal lung liquid secretion in sheep
Perry Recognition and management
van Galen et al. The artificial placenta: Development of a lung and kidney assist device for criticallly ill preterm neonates
Ebersohn et al. Continuous renal replacement therapy
Varghese Renal replacement therapy in acute kidney failure–An overview
Hagland The management of acute renal failure in the intensive therapy unit
Muelenaer A new blood pump and oxygenator system for support of infants with neonatal respiratory distress: preliminary in vitro and in vivo evaluation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240501